Role of pacing in the treatment of vasovagal syncope11This article may contain discussion of off-label or investigational uses (not yet approved by the FDA) of various therapeutic agents. Please refer to the box provided on page 2Q of this supplement for a disclosure of such agents.

This publication has 36 references indexed in Scilit:

• The North American vasovagal pacemaker study (VPS)
  Journal of the American College of Cardiology, 1999
• Effect of Dual-Chamber Pacing With Automatic Rate-Drop Sensing on Recurrent Neurally Mediated Syncope
  The American Journal of Cardiology, 1998
• Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope
  European Heart Journal, 1997
• Clinical Experience with Thera DR Rate‐Drop Response Pacing Algorithm in Carotid Sinus Syndrome and Vasovagal Syncope
  Pacing and Clinical Electrophysiology, 1997
• Recurrence of neurocardiogenic syncope without pharmacologic interventions
  The American Journal of Cardiology, 1996
• Risk Factors for Syncope Recurrence After a Positive Tilt-Table Test in Patients With Syncope
  Circulation, 1996
• Permanent pacing for cardioinhibitory malignant vasovagal syndrome.
  Heart, 1994
• Recommendations for pacemaker prescription for symptomatic bradycardia
  Heart, 1991
• Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (committee on pacemaker implantation)
  Journal of the American College of Cardiology, 1991
• Epidemiologic features of isolated syncope: the Framingham Study.
  Stroke, 1985